These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 23709210

  • 1. Natalizumab therapy for multiple sclerosis.
    Derfuss T, Kuhle J, Lindberg R, Kappos L.
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [Abstract] [Full Text] [Related]

  • 2. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ, Hogg JP.
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [Abstract] [Full Text] [Related]

  • 3. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 4. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 01; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 01; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL.
    Neurol Res; 2006 Apr 01; 28(3):291-8. PubMed ID: 16687056
    [Abstract] [Full Text] [Related]

  • 7. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 8. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 17; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 17; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 10. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
    Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.
    Arch Neurol; 2007 Feb 17; 64(2):169-76. PubMed ID: 17296831
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Feb 17; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 12. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 13. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 29; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S, Weinstock-Guttman B.
    Expert Opin Biol Ther; 2014 Jan 29; 14(1):115-26. PubMed ID: 24289270
    [Abstract] [Full Text] [Related]

  • 15. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Jan 29; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 16. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
    Takao M.
    Brain Nerve; 2013 Nov 29; 65(11):1363-74. PubMed ID: 24200614
    [Abstract] [Full Text] [Related]

  • 17. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.
    Expert Opin Biol Ther; 2016 Sep 29; 16(9):1151-62. PubMed ID: 27413840
    [Abstract] [Full Text] [Related]

  • 18. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2016 Sep 29; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 19. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC, Hecht EM.
    Clin Neuropharmacol; 2014 Sep 29; 37(2):45-51. PubMed ID: 24614671
    [Abstract] [Full Text] [Related]

  • 20. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 29; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.